Skip to main content
Erschienen in: International Urology and Nephrology 11/2021

11.08.2021 | Urology - Original Paper

Clinicopathological patterns of bladder carcinoma over 1 year: experience from University Hospital of Nepal

verfasst von: Purushottam Parajuli, Bhoj Raj Luitel, Manish Man Pradhan, Suman Chapagain, Sujeet Poudyal, Sampanna Chudal, Bipin Guragain, Durga Pandit, Diwas Gnyawali, Prem Raj Sigdel, Pawan Raj Chalise, Uttam Kumar Sharma

Erschienen in: International Urology and Nephrology | Ausgabe 11/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To define the clinical and pathological patterns of urinary bladder carcinoma from the University Hospital of Nepal.

Methods

This is a retrospective analytical study. Patients with bladder mass who underwent surgery over 1 year and who had data record were included in the study. Demographic profile, type of surgery, findings on clinical examination, cystoscopy findings, histopathological report, tumor stage, and post-surgery adjuvant therapy were analyzed.

Results

Out of 86 patients who underwent transurethral resection of bladder tumor, 77 patients had biopsy-proven malignant bladder tumor. Urothelial cancer was present in 96.1%. Male were 78.6%. The mean age of diagnosis was 65.5 ± 11.8 years. Non-muscle-invasive bladder cancer (NMIBC) was 3.7 times more common than muscle-invasive bladder cancer (MIBC). High-grade tumors (58.6%) were more common than low grade (41.4%). The detrusor muscle was present inthe biopsy specimen of 48 patients (64%). Re-TURBT within 2–6 weeks was considered based on histopathology reports for about half of the patients (45.3%). Upstaging and upgrading of the tumor was present in 5.8 and 5.8% of the patients, respectively. Residual tumor without upstaging and upgrading was present in 23.5%. One patient (1.3%) had Clavien–Dindo grade 1, three (4%) patients had grade 2 and two patients (2.7%) had grade 3b.

Conclusion

In the present study, patients with bladder cancer are younger than reported in other studies. Smokers are strongly predisposed. The histological pattern is similar to the Western and Asian populations. NMIBC and MIBC occur in proportion to that described as in other studies. We had a lower rate of recurrence, upstaging and upgrading. We had a lesser rate of acceptance for radical cystectomy in our patients.
Literatur
9.
Zurück zum Zitat Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, Sarosdy MF, Bohl RD, Grossman HB, Beck TM, Leimert JT, Crawford ED (2000) Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 163(4):1124–1129. https://pubmed.ncbi.nlm.nih.gov/10737480/ Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, Sarosdy MF, Bohl RD, Grossman HB, Beck TM, Leimert JT, Crawford ED (2000) Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 163(4):1124–1129. https://​pubmed.​ncbi.​nlm.​nih.​gov/​10737480/​
11.
15.
18.
Zurück zum Zitat Mariappan P, Zachou A, Grigor KM, Edinburgh Uro-Oncology Group (2010) Detrusor muscle in the first, apparently complete transurethral resection of bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience. Eur Urol 57(5):843–849. https://pubmed.ncbi.nlm.nih.gov/19524354/ Mariappan P, Zachou A, Grigor KM, Edinburgh Uro-Oncology Group (2010) Detrusor muscle in the first, apparently complete transurethral resection of bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience. Eur Urol 57(5):843–849. https://​pubmed.​ncbi.​nlm.​nih.​gov/​19524354/​
19.
Zurück zum Zitat Babjuk M, Böhle A, Burger M, Capoun O, Cohen D, Compérat EM, Hernández V, Kaasinen E, Palou J, Rouprêt M, van Rhijn BWG, Shariat SF, Soukup V, Sylvester RJ, Zigeuner R (2017) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol 71(3):447–461. https://pubmed.ncbi.nlm.nih.gov/27324428/ Babjuk M, Böhle A, Burger M, Capoun O, Cohen D, Compérat EM, Hernández V, Kaasinen E, Palou J, Rouprêt M, van Rhijn BWG, Shariat SF, Soukup V, Sylvester RJ, Zigeuner R (2017) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol 71(3):447–461. https://​pubmed.​ncbi.​nlm.​nih.​gov/​27324428/​
20.
Zurück zum Zitat Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR, Pruthi R, Quale DZ, Ritch CR, Seigne JD, Skinner EC, Smith ND, McKiernan JM (2016) Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. J Urol 196(4):1021–1029. https://pubmed.ncbi.nlm.nih.gov/27317986/ Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR, Pruthi R, Quale DZ, Ritch CR, Seigne JD, Skinner EC, Smith ND, McKiernan JM (2016) Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. J Urol 196(4):1021–1029. https://​pubmed.​ncbi.​nlm.​nih.​gov/​27317986/​
25.
Zurück zum Zitat Baltacı S, Bozlu M, Yıldırım A, Gökçe Mİ, Tinay İ, Aslan G, Can C, Türkeri L, Kuyumcuoğlu U, Mungan A (2015) Significance of the interval between first and second transurethral resection on recurrence and progression rates in patients with high-risk non-muscle-invasive bladder cancer treated with maintenance intravesical Bacillus Calmette-Guérin. BJU Int 116(5):721–726. https://pubmed.ncbi.nlm.nih.gov/25715815/ Baltacı S, Bozlu M, Yıldırım A, Gökçe Mİ, Tinay İ, Aslan G, Can C, Türkeri L, Kuyumcuoğlu U, Mungan A (2015) Significance of the interval between first and second transurethral resection on recurrence and progression rates in patients with high-risk non-muscle-invasive bladder cancer treated with maintenance intravesical Bacillus Calmette-Guérin. BJU Int 116(5):721–726. https://​pubmed.​ncbi.​nlm.​nih.​gov/​25715815/​
28.
Zurück zum Zitat Shukla SK, Chandra S, Chauhan N, Sarpal R (2021) Expression of CD10 in urothelial carcinoma of the bladder and its correlation with histopathological grade, pathological stage, and survival of patients. J Can Res Ther [Epub ahead of print] Shukla SK, Chandra S, Chauhan N, Sarpal R (2021) Expression of CD10 in urothelial carcinoma of the bladder and its correlation with histopathological grade, pathological stage, and survival of patients. J Can Res Ther [Epub ahead of print]
30.
Zurück zum Zitat Sylvester RJ, Oosterlinck W, Holmang S, Sydes MR, Birtle A, Gudjonsson S, De Nunzio C, Okamura K, Kaasinen E, Solsona E, Ali-El-Dein B, Tatar CA, Inman BA, N'Dow J, Oddens JR, Babjuk M (2016) Systematic review and individual patient data meta-analysis of randomized trials comparing a single immediate instillation of chemotherapy after transurethral resection with transurethral resection alone in patients with stage pTa-pT1 urothelial carcinoma of the bladder: which patients benefit from the instillation? Eur Urol 69(2):231–244. https://pubmed.ncbi.nlm.nih.gov/26091833/ Sylvester RJ, Oosterlinck W, Holmang S, Sydes MR, Birtle A, Gudjonsson S, De Nunzio C, Okamura K, Kaasinen E, Solsona E, Ali-El-Dein B, Tatar CA, Inman BA, N'Dow J, Oddens JR, Babjuk M (2016) Systematic review and individual patient data meta-analysis of randomized trials comparing a single immediate instillation of chemotherapy after transurethral resection with transurethral resection alone in patients with stage pTa-pT1 urothelial carcinoma of the bladder: which patients benefit from the instillation? Eur Urol 69(2):231–244. https://​pubmed.​ncbi.​nlm.​nih.​gov/​26091833/​
31.
Zurück zum Zitat Comploj E, Dechet CB, Mian M, Trenti E, Palermo S, Lodde M, Mian C, Ambrosini-Spaltro A, Horninger W, Pycha A (2014) Perforation during TUR of bladder tumours influences the natural history of superficial bladder cancer. World J Urol 32(5):1219–1223. https://pubmed.ncbi.nlm.nih.gov/24166290/ Comploj E, Dechet CB, Mian M, Trenti E, Palermo S, Lodde M, Mian C, Ambrosini-Spaltro A, Horninger W, Pycha A (2014) Perforation during TUR of bladder tumours influences the natural history of superficial bladder cancer. World J Urol 32(5):1219–1223. https://​pubmed.​ncbi.​nlm.​nih.​gov/​24166290/​
Metadaten
Titel
Clinicopathological patterns of bladder carcinoma over 1 year: experience from University Hospital of Nepal
verfasst von
Purushottam Parajuli
Bhoj Raj Luitel
Manish Man Pradhan
Suman Chapagain
Sujeet Poudyal
Sampanna Chudal
Bipin Guragain
Durga Pandit
Diwas Gnyawali
Prem Raj Sigdel
Pawan Raj Chalise
Uttam Kumar Sharma
Publikationsdatum
11.08.2021
Verlag
Springer Netherlands
Erschienen in
International Urology and Nephrology / Ausgabe 11/2021
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-021-02969-6

Weitere Artikel der Ausgabe 11/2021

International Urology and Nephrology 11/2021 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.